TLR9 and B-cell chronic lymphocytic leukemia: In this way, ibrutinib inhibits BCR signaling efficaciously but partially the TLR signaling [67] being TLR9 signaling activation a common escape mechanism after treatment of CLL cells with ibrutinib and venetoclax [68].